Vanda's sleep-disorder drug tasimelteon wins FDA panel support

11/14/2013 | Reuters · American City Business Journals

An FDA advisory panel endorsed the approval of Vanda Pharmaceuticals' tasimelteon as a treatment for non-24-hour sleep-wake disorder in blind people. If approved, the drug would be sold under the brand name Hetlioz. A final decision is expected by Jan. 31.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC